WithdrawnPhase 1NCT03057509
A Pilot Study Of Ga-68-DOTA-TOC Imaging In Participants With Small Bowel Carcinoid Tumors
Studying Neuroendocrine tumor of the small intestine
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Massachusetts General Hospital
- Principal Investigator
- Umar Mahmood, MD, PhDMassachusetts General Hospital
- Intervention
- Ga-68-DOTA-TOC(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2021
Study locations (2)
- Massachusetts general Hospital, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03057509 on ClinicalTrials.govOther trials for Neuroendocrine tumor of the small intestine
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT04735198Prophylactic Cholecystectomy in Midgut NETs Patients Who Require Primary Tumor Surgery.Hospital Universitari de Bellvitge
- ACTIVE NOT RECRUITINGNCT03498040Development and Progression of Carcinoid Heart Disease in a Cohort of Adult Patients With Neuroendocrine TumorsHospices Civils de Lyon
See all trials for Neuroendocrine tumor of the small intestine →